Agree - this mob is not into positive shareholder relations and never has been - that is despite promised that they would improve that situation.
However, the antiviral sector is crying out for new medicines and maybe, just maybe, BIT225 could be seen by Biotech firms as a chance to do that. personally, I think it is a very long shot though.
I also think that any movement will not provide BIT with any material financial benefit that would allow the company to continue operations, and it will fold in 2025.
It may, however, give shareholders a small return on their investment.
BIT has been poorly managed for many years, and its financial management has been appalling. The day of wine and roses are quickly coming to an end for the BOD - and to the extreme detriment of long suffering shareholders whom I do have genuine sympathy for.
That would be tempered by the question of why many have stayed the journey this long - well after the writing on the wall suggested that BIT is a lost cause.
BIT Price at posting:
0.3¢ Sentiment: Sell Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)